Novartis investors turn spotlight on M&A after trial setbacks
Novartis investors are scrutinizing its M&A strategy after recent drug trial setbacks, including the failure of del-desiran, which led to an 11% share price drop. Concerns focus on the $12B Avidity acquisition and future patent expirations. CEO Vas Narasimhan faces pressure to adjust the approach, with some investors calling for smaller, targeted deals. Despite setbacks, some shareholders remain confident in the company's pipeline and management.
How this was made
The 30-second read
Why it matters
The 11% share drop wipes out $30 bn in market value, signaling immediate risk for investors and prompting calls for tighter M&A oversight.
Market read
The news directly affects Novartis stock and may influence broader pharma M&A sentiment.
What to watch
The upcoming remibrutinib data in October could offset the current negative sentiment if results are positive.
Background
Novartis has spent over $30 bn on acquisitions in the past three years, including the $12 bn Avidity purchase. Recent trial failures raise questions about the value of these deals.
Ticker impact
Novartis shares fell 11% after the late‑stage failure of the del‑desiran drug, raising concerns over its recent $12 bn Avidity acquisition.
Further downside pressure if additional pipeline candidates disappoint; potential short‑term bounce if management outlines corrective actions.
An 11% move on the day of the news reflects strong market reaction; the size of the loss ($30 bn) and the link to a recent large acquisition make the impact material.
Market effects
The setback may dampen investor appetite for large pharma M&A deals and increase scrutiny of other biotech acquisitions.
European pharma stocks could see heightened volatility as peers are compared to Novartis' pipeline risk.
Large‑cap pharma index exposure may be adjusted by global funds reacting to the trial failure.
Counterpoint
If Novartis can successfully commercialize its remaining Avidity assets, the stock may be oversold and present a buying opportunity.
Key entities
- companyNovartis
Swiss pharmaceutical giant (ticker NVS).
- companyAvidity Biosciences
Acquired by Novartis for $12 bn.
